Lendermon Elizabeth A, Dodd-o Jeffrey M, Coon Tiffany A, Miller Hannah L, Ganguly Sudipto, Popescu Iulia, O'Donnell Christopher P, Cardenes Nayra, Levine Melanie, Rojas Mauricio, Weathington Nathaniel M, Zhao Jing, Zhao Yutong, McDyer John F
1 Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and.
Am J Respir Cell Mol Biol. 2015 May;52(5):622-33. doi: 10.1165/rcmb.2014-0059OC.
Acute cellular rejection is a known risk factor for the development of obliterative bronchiolitis, which limits the long-term survival of lung transplant recipients. However, the T cell effector mechanisms in both of these processes remain incompletely understood. Using the mouse orthotopic lung transplant model, we investigated whether C57BL/6 T-bet(-/-) recipients of major histocompatibility complex (MHC)-mismatched BALB/c lung grafts develop rejection pathology and allospecific cytokine responses that differ from wild-type mice. T-bet(-/-) recipients demonstrated vigorous allograft rejection at 10 days, characterized by neutrophilic inflammation and predominantly CD8(+) T cells producing allospecific IL-17 and/or IFN-γ, in contrast to IFN-γ-dominant responses in WT mice. CD4(+) T cells produced IL-17 but not IFN-γ responses in T-bet(-/-) recipients, in contrast to WT controls. Costimulation blockade using anti-CD154 Ab significantly reduced allospecific CD8(+)IFN-γ(+) responses in both T-bet(-/-) and WT mice but had no attenuating effect on lung rejection pathology in T-bet(-/-) recipients or on the development of obliterative airway inflammation that occurred only in T-bet(-/-) recipients. However, neutralization of IL-17A significantly attenuated costimulation blockade-resistant rejection pathology and airway inflammation in T-bet(-/-) recipients. In addition, CXCL1 (neutrophil chemokine) was increased in T-bet(-/-) allografts, and IL-17 induced CXCL1 from mouse lung epithelial cells in vitro. Taken together, our data show that T-bet-deficient recipients of complete MHC-mismatched lung allografts develop costimulation blockade-resistant rejection characterized by neutrophilia and obliterative airway inflammation that is predominantly mediated by CD8(+)IL-17(+) T cells. Our data support T-bet-deficient mouse recipients of lung allografts as a viable animal model to study the immunopathogenesis of small airway injury in lung transplantation.
急性细胞排斥反应是闭塞性细支气管炎发生的已知危险因素,而闭塞性细支气管炎会限制肺移植受者的长期存活。然而,这两个过程中的T细胞效应机制仍未完全明确。我们使用小鼠原位肺移植模型,研究了主要组织相容性复合体(MHC)不匹配的BALB/c肺移植的C57BL/6 T-bet基因敲除(-/-)受者是否会出现与野生型小鼠不同的排斥病理和同种异体特异性细胞因子反应。T-bet(-/-)受者在第10天表现出强烈的同种异体移植排斥反应,其特征为嗜中性粒细胞炎症,主要是产生同种异体特异性白细胞介素-17(IL-17)和/或干扰素-γ(IFN-γ)的CD8(+)T细胞,这与野生型小鼠中以IFN-γ为主的反应形成对比。与野生型对照相比,在T-bet(-/-)受者中,CD4(+)T细胞产生IL-17但不产生IFN-γ反应。使用抗CD154抗体进行共刺激阻断可显著降低T-bet(-/-)和野生型小鼠中的同种异体特异性CD8(+)IFN-γ(+)反应,但对T-bet(-/-)受者的肺排斥病理或仅在T-bet(-/-)受者中发生的闭塞性气道炎症的发展没有减轻作用。然而,中和IL-17A可显著减轻T-bet(-/-)受者中抗共刺激阻断的排斥病理和气道炎症。此外,T-bet(-/-)同种异体移植中CXC趋化因子配体1(CXCL1,嗜中性粒细胞趋化因子)增加,并且IL-17在体外可诱导小鼠肺上皮细胞产生CXCL1。综上所述,我们的数据表明,完全MHC不匹配的肺同种异体移植的T-bet缺陷受者会出现抗共刺激阻断的排斥反应,其特征为嗜中性粒细胞增多和闭塞性气道炎症,主要由CD8(+)IL-17(+)T细胞介导。我们的数据支持肺同种异体移植的T-bet缺陷小鼠受者作为研究肺移植中小气道损伤免疫发病机制的可行动物模型。